Aralez Bio

Aralez Bio is a private, early-stage biotech leveraging a proprietary enzyme engineering platform to synthesize noncanonical amino acids (ncAAs) for drug discovery and development. Founded in 2021, the company addresses a critical supply chain bottleneck by providing a greener, more scalable alternative to traditional chemical synthesis for these specialized building blocks. Its platform is designed for continuity from milligram to commercial scale, reducing development timelines and manufacturing risks for partners. Aralez is in an early revenue stage, generating income through the sale of catalog and custom ncAAs, and has recently closed a Series A financing round to advance its platform and commercial efforts.

Proprietary enzyme engineering platform using directed evolution and biocatalysis for the scalable, sustainable synthesis of noncanonical amino acids (ncAAs).

Aralez competes with traditional fine chemical and custom synthesis companies that use multi-step organic chemistry to produce ncAAs, often with longer lead times and less sustainable processes. It may also face future competition from other synthetic biology startups applying enzyme engineering to chemical synthesis, though Aralez's specific focus on ncAAs for drug development provides a targeted niche.